Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,544,580
  • Shares Outstanding, K 60,846
  • Annual Sales, $ 289,590 K
  • Annual Income, $ 66,860 K
  • 60-Month Beta 2.74
  • Price/Sales 9.24
  • Price/Cash Flow 33.92
  • Price/Book 2.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.09
  • Number of Estimates 7
  • High Estimate -0.96
  • Low Estimate -1.17
  • Prior Year -0.93
  • Growth Rate Est. (year over year) -17.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.30 +37.12%
on 03/16/20
54.61 -18.90%
on 03/02/20
-9.16 (-17.14%)
since 02/28/20
3-Month
32.30 +37.12%
on 03/16/20
66.05 -32.94%
on 12/30/19
-21.72 (-32.90%)
since 12/27/19
52-Week
32.30 +37.12%
on 03/16/20
74.00 -40.15%
on 12/04/19
+8.57 (+23.99%)
since 03/29/19

Most Recent Stories

More News
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $39.54, moving +1.49% from the previous trading session.

CRSP : 44.29 (+5.91%)
Sickle Cell Anemia Industry Outlook to 2026 Featuring CRISPR Therapeutics, Global Blood Therapeutics, Novartis, Pfizer, and Vertex Pharmaceuticals

The "Market Spotlight: Sickle Cell Anemia" report has been added to ResearchAndMarkets.com's offering.

CRSP : 44.29 (+5.91%)
GBT : 52.04 (+1.80%)
NVS : 81.90 (+3.30%)
VRTX : 231.92 (+6.76%)
First Week of CRSP May 1st Options Trading

Investors in CRISPR Therapeutics AG saw new options begin trading this week, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain...

CRSP : 44.29 (+5.91%)
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $44.67 in the latest trading session, marking a +0.84% move from the prior day.

CRSP : 44.29 (+5.91%)
Horrible Week Finally Comes to an End

Horrible Week Finally Comes to an End

TQQQ : 49.00 (+10.51%)
CURE : 40.34 (+13.99%)
SGMO : 6.49 (+2.37%)
TTD : 197.51 (-1.09%)
JPM : 93.50 (+2.60%)
ACCO : 5.00 (-2.91%)
NTLA : 12.68 (+6.38%)
GH : 71.25 (+5.10%)
CRSP : 44.29 (+5.91%)
CRISPR Therapeutics Proposes Changes to the Board of Directors

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its...

RUBY : 4.49 (+4.66%)
CRSP : 44.29 (+5.91%)
RARX : 47.34 (+0.94%)
What's in Store for Vertex in 2020 After a Remarkable 2019?

In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.

REGN : 473.00 (+5.22%)
MRNA : 30.48 (+1.43%)
VRTX : 231.92 (+6.76%)
CRSP : 44.29 (+5.91%)
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

-Enrollment ongoing in clinical trials of CTX001(TM) for patients with severe hemoglobinopathies-

CRSP : 44.29 (+5.91%)
Back from the Weekend and Back to New Highs

Back from the Weekend and Back to New Highs

SAVE : 12.42 (-16.02%)
DKS : 22.14 (+1.84%)
BBY : 59.75 (-4.35%)
ADNT : 9.35 (+1.96%)
AL : 21.82 (+4.25%)
MTW : 8.15 (+3.43%)
CAE : 12.76 (-4.20%)
OLED : 137.35 (+2.45%)
NTLA : 12.68 (+6.38%)
CRSP : 44.29 (+5.91%)
EDIT : 20.25 (+1.45%)
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day.

CRSP : 44.29 (+5.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Trade CRSP with:

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 47.13
1st Resistance Point 45.71
Last Price 44.29
1st Support Level 41.72
2nd Support Level 39.15

See More

52-Week High 74.00
Fibonacci 61.8% 58.07
Fibonacci 50% 53.15
Fibonacci 38.2% 48.23
Last Price 44.29
52-Week Low 32.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar